Mahtab Marker

Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial

A. Ari Hakimi, Martin H. Voss, Fengshen Kuo et al. · Cancer Discovery · 2019 · 286 citations

Medicine, Oncology, Pharmacology +17

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

Robert J. Motzer, Camillo Porta, Nicholas J. Vogelzang et al. · The Lancet Oncology · 2014 · 263 citations · Full text

Medicine, Oncology, Pharmacology +12

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

James J. Hsieh, David Chen, Patricia I. Wang et al. · European Urology · 2016 · 203 citations · Full text

Medicine, Genetics, Oncology +16

Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study

Martin H. Voss, Albert Reising, Parul Patel et al. · The Lancet Oncology · 2018 · 145 citations

Medicine, Bioinformatics, Oncology +16

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Jennifer J. Knox, Carlos H. Barrios, T.M. Kim et al. · Annals of Oncology · 2017 · 107 citations · Full text

Medicine, Oncology, Pharmacology +17